Groundbreaking research in a wide variety of organisms has begun to address fundamental questions regarding the evolutionary origin of mesoderm and how patterning of this emergent tissue layer has played a central role in the diversification of metazoan body plans. However, attempts to synthesize this growing body of research have been limited. To address this perceived gap, a symposium entitled "Movers and Shakers: The Evolution and Development of Mesoderm" was held at the 2006 Society for Integrative and Comparative Biology Conference in Orlando, Florida. The papers derived from this symposium cover a broad range of organisms and approaches. It was our intention that integration of the data and methodologies from these diverse research programs would generate new hypotheses and collaborative efforts to decipher fundamental questions of mesoderm development and evolution.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1002/jez.b.21199 | DOI Listing |
Commun Biol
December 2024
Tianjin Key Laboratory of Industrial Biological Systems and Process Engineering, Tianjin Institute of Industrial Biotechnology, Chinese Academy of Sciences, Tianjin, 300308, China.
Despite a lot of efforts devoted to construct efficient microbiomes, there are still major obstacles to moving from the lab to industrial applications due to the inapplicability of existing technologies or limited understanding of microbiome variation regularity. Here we show a domestication strategy to cultivate an effciient and resilient functional microbiome for addressing phenolic wastewater challenges, which involves directional domestication in shaker, laboratory water test in small-scale, gas test in pilot scale, water test in pilot scale, and engineering application in industrial scale. The domestication process includes the transition from water to gas, which provided complex transient environment for screening of a more adaptable and robust microbiome, thereby mitigating the performance disparities encountered when transitioning from laboratory experimentation to industrial engineering applications.
View Article and Find Full Text PDFJ Allergy Clin Immunol Pract
December 2024
Section of Allergy and Immunology, Children's Hospital Colorado, Department of Pediatrics, University of Colorado School of Medicine. Electronic address:
The current FDA paradigm may not fully capture important patient-centered outcomes or measure a primary outcome that is truly meaningful to patients. Patient reported outcome measures (PROMs) are standardized tools measuring the patient's experience in food allergy clinical trials, which can help support shared decision-making (SDM) and further our understanding of treatment impact. Food allergy PROMs include quality of life (QoL), health state utility (HSU), severity, and self-efficacy measures.
View Article and Find Full Text PDFNPJ Antimicrob Resist
November 2024
Department of Molecular and Cellular Biology, University of Guelph, Guelph, ON N1H 5N4 Canada.
Antimicrobial-induced DNA damage, and subsequent repair via upregulation of DNA repair factors, including error-prone translesion polymerases, can lead to the increased accumulation of mutations in the microbial genome, and ultimately increased risk of acquired mutations associated with antimicrobial resistance. While this phenotype is well described in bacterial species, it is less thoroughly investigated amongst microbial fungi. Here, we monitor DNA damage induced by antifungal agents in the fungal pathogen , and find that commonly used antifungal drugs are able to induce DNA damage, leading to the upregulation of transcripts encoding predicted error-prone polymerases and related factors.
View Article and Find Full Text PDFAllergy Asthma Proc
November 2024
From the Section of Allergy and Immunology, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire.
Int J Surg Pathol
October 2024
Department of Pathology and Laboratory Medicine, University of California San Francisco, San Francisco, CA, USA.
Objective: Chronic kidney disease is a growing global health issue, contributing significantly to morbidity and mortality. The incidence of end-stage renal disease (ESRD) is approximately 100 per million population. Renal transplantation remains the cornerstone treatment for ESRD, with a projected 20-year survival rate of 60%.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!